BSECompany Update1d ago · 19 Oct 2026, 02:44 pm
Acquisition of Land for Manufacturing Expansion at Amritsar
Kwality Pharmaceuticals Ltd · 539997
✦ AI Summary▲ PositiveExpansion
Kwality Pharmaceuticals Ltd has acquired 4 acres of land adjacent to its existing manufacturing facility in Amritsar, Punjab, to support its next phase of growth. The company plans to develop a fully automated manufacturing facility with 10 production lines, meeting EU GMP requirements, to meet growing demand for existing and upcoming products, create capacity for future launches, and strengthen its Amritsar manufacturing campus.
Analysis Scores
Earnings Impact8/10
Growth Catalyst9/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment8/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Kwality Pharmaceuticals Ltd - 539997 - Acquisition Of Land For Manuufacturing Expansion At Amritsar
Attachments (1)
📄pdf
Download →
0262eb06-f1af-4a40-9305-caf6eabba3d7.pdf
View document text
GIN No. L24232PB1983PLC005426 GST No. 03AAACK6458M1ZB Phone : 91-8558820862 (Accounts)
: 91-8558820863 (Admin.)
D.L. No. 1800-0SP, 1804-B I.E. Code No. 1293001210
: 91-9915743720 (Exports)
KWALITY PHARMACEUTICALS LIMITED M.D. Mobile: 91-9814071215, 9814052314
E-mail : export@kwalitypharma.com
Regd. Office: Village Nag KaIan, Majitha Road, Amritsar - 143 601 (INDIA) ramesh@kwalitypharma.com
Website : www.kwalitypharma.com
Date: 19/10/2026
Department of Corporate Services,
BSE Limited
25th Floor, P.J. Towers, Dalal Street
Mumbai-400001
Scrip Code: 539997
Subject: Acquisition of Land for Manufacturing Expansion at Amritsar, Punjab
Kwality Pharmaceuticals Limited is pleased to announce the acquisition of 4 acres of
land adjacent to its existing manufacturing facility in Amritsar, Punjab, to support
its next phase of growth.
The Company plans to develop a fully automated manufacturing facility comprising
4 injectable lines and 6+ lines for tablets, capsules, ophthalmic and other oral
solid dosage formulations, designed with due consideration to applicable EU GMP
requirements, including Annex 1, wherever relevant.
The expansion aims to meet growing demand for existing and upcoming products,
create capacity for future launches and bioequivalence-led opportunities, and
strengthen the Company's Amritsar manufacturing campus.
The project is targeted for completion by Q4 FY2028, with full operations expected by
Q2 FY2029, reinforcing the Company's commitment to scalable capacity and
sustainable growth.
For Kwality Pharma
Ramesh Kumar
Managing Director